Qorvo Biotechnologies Granted FDA Emergency use Authorization for Rapid Covid-19 Antigen Testing

Qorvo, a leading provider of innovative radio frequency (RF) solutions that connect the world, announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the Qorvo Omnia SARS-CoV-2 Antigen Test Solution. The test is authorized for the qualitative detection of nucleocapsid viral antigens from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of COVID-19.

Using Bulk Acoustic Wave (BAW) technology, the Qorvo Omnia™ platform is designed to deliver rapid results for SARS-CoV-2 antigen and antibody tests. BAW enables surface-based mass measurement using high frequency and surface binding. BAW allows for multiplexing (multiple analytes from a single sample) and the test cartridge is designed to measure across multiple sample matrices such as whole blood, serum, plasma, saliva and more. The goal is to enable clinicians' access to test data in minutes.

The Qorvo Omnia platform represents a paradigm shift in diagnostic testing capability by using high-frequency Bulk Acoustic Wave (BAW) sensors to achieve SARS-CoV-2 (COVID-19) antigen testing in approximately 20 minutes. BAW sensor technology enables low Limit of Detection (LOD) levels that are similar to molecular testing capability.

The Qorvo Omnia platform features a portable test instrument, microfluidic cartridge, and secure connectivity. The microfluidic cartridge design enables specific binding with additional wash steps similar to central lab instrument operation and demonstrated results including 100% specificity during clinical trials.

Fred S. Apple, Ph.D., a member of Qorvo Biotechnologies’ advisory board, Co-Medical Director of Toxicology Laboratory at Hennepin Healthcare/Hennepin County Medical Center, and Professor of Laboratory Medicine & Pathology at the University of Minnesota, said, “This is very exciting news. FDA authorization of Qorvo’s Omnia Antigen Test provides a rapid, sensitive, and specific assessment of individuals, assisting providers trying to either rule in or rule out COVID-19, comparable to many of the PCR testing platforms in use. The testing system will hopefully be an avenue to assist in opening up the United States to be closer to business as usual.”

James Klein, President of Qorvo Biotechnologies, said, “The FDA’s EUA is recognition that the Qorvo Omnia platform can help address the ongoing need for rapid, accurate and clinically-reliable diagnostic testing. We are honored to leverage Qorvo’s technology portfolio to help public health officials respond to this global pandemic.”

Click here to learn more about Qorvo Omnia SARS-CoV-2 Antigen Test Solution.


  • Country: United States
More news from Qorvo